Search

Gene Therapy Reset: Astellas Retries XLMTM After Deaths with a Safer V

Astellas reenters clinic with next-gen XLMTM gene therapy after fatal trial. Meanwhile, Intellia's CRISPR cuts swelling attacks by 87% in Phase 3. The new AAV8